Key Advance Toward Treatment For Most Common Adult Form Of Muscular Dystrophy – Journal Of The American Chemical Society

Scientists in New York are reporting a critical first step toward development of a long-sought drug to treat myotonic muscular dystrophy (MMD), the most common form of muscular dystrophy in adults. MMD affects about 1 in 8,000 people. Their findings appeared in the November 8 issue of ACS' weekly Journal of the American Chemical Society. In the study, Benjamin Miller and colleagues point out that MMD differs from typical hereditary diseases.